SEC Comment Letter for Replimune Group, Inc. (REPL) (CIK 0001737953) (REPL) — Jun 2, 2025
Replimune Group, Inc. (REPL) (CIK 0001737953)
Date: June 2, 2025 · CIK: 0001737953 · Accession: 0000000000-25-005775
AI Filing Summary & Sentiment
File numbers found in text: 333-287536
Letter
May 30, 2025 Sushil Patel Chief Executive Officer Replimune Group, Inc. 500 Unicorn Park Drive, Suite 303 Woburn, MA 01801 Re:Replimune Group, Inc. Registration Statement on Form S-3 Filed May 23, 2025 File No. 333-287536 Dear Sushil Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Benjamin J. Stein, Esq.
Show Raw Text
May 30, 2025
Sushil Patel
Chief Executive Officer
Replimune Group, Inc.
500 Unicorn Park Drive, Suite 303
Woburn, MA 01801
Re:Replimune Group, Inc.
Registration Statement on Form S-3
Filed May 23, 2025
File No. 333-287536
Dear Sushil Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Benjamin J. Stein, Esq.